E Fund Management Co. Ltd. Has $549,000 Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

E Fund Management Co. Ltd. lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 27.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 7,421 shares of the medical research company’s stock after purchasing an additional 1,583 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Exact Sciences were worth $549,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of EXAS. Wolff Wiese Magana LLC grew its position in shares of Exact Sciences by 459.5% in the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 340 shares during the period. Cullen Frost Bankers Inc. lifted its stake in Exact Sciences by 40.0% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 200 shares in the last quarter. Valley National Advisers Inc. lifted its stake in Exact Sciences by 29.5% in the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 176 shares in the last quarter. Milestone Investment Advisors LLC bought a new stake in Exact Sciences in the 3rd quarter valued at approximately $57,000. Finally, National Bank of Canada FI lifted its stake in Exact Sciences by 30.9% in the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 200 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the topic of several research reports. Canaccord Genuity Group cut their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. TheStreet cut Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. Finally, Citigroup restated a “buy” rating and issued a $100.00 target price on shares of Exact Sciences in a research note on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $99.07.

Insiders Place Their Bets

In other news, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Kevin T. Conroy sold 1,155 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin T. Conroy sold 14,791 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the sale, the chief executive officer now owns 1,224,357 shares in the company, valued at approximately $75,212,250.51. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 70,611 shares of company stock valued at $4,255,377. 1.30% of the stock is currently owned by insiders.

Exact Sciences Price Performance

EXAS stock traded down $1.93 during midday trading on Wednesday, reaching $59.48. The company had a trading volume of 3,635,258 shares, compared to its average volume of 2,288,033. The company has a market capitalization of $10.94 billion, a price-to-earnings ratio of -52.18 and a beta of 1.26. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. Exact Sciences Co. has a 1-year low of $56.05 and a 1-year high of $100.77. The stock has a 50 day moving average price of $63.64 and a 200-day moving average price of $64.66.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The company had revenue of $646.89 million during the quarter, compared to analysts’ expectations of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. Exact Sciences’s revenue was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.72) EPS. Equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.